The Losartan intervention for endpoint reduction (LIFE) trial - Have angiotensin-receptor blockers come of age?

Journal of Clinical Hypertension

Volumn 4, Issue 4, 2002, Pages 301-305

  Sica, Domenic A ^a   Weber, Michael ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SUNY Downstate Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE; LOSARTAN; RAMIPRIL; VALSARTAN;

ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; ELECTROCARDIOGRAPHY; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MORTALITY; STROKE;

EID: 0036344509     PISSN: 15246175     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1524-6175.2002.01099.x     Document Type: Article

References (29)

1. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol
2. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol
3. Progressive hypertrophy regression with sustained pressure reduction in hypertension: The Losartan Intervention For Endpoint reduction study
4. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial
5. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: A randomized controlled trial
6. Stroke is more common than myocardial infarction in hypertension: Analysis based on 11 major randomised intervention trials
7. Use of ramipril in preventing stroke: Double blind randomised trial
8. Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension
9. Reduction in arterial stiffness with angiotensin II antagonist is comparable with and additive to ACE inhibition
10. The effect of antihypertensive drugs on vascular compliance
11. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan
12. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
13. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial
14. Ramipril and the development of diabetes
15. Differential effects of ACE-inhibition and angiotensin II antagonism on fibrinolysis and insulin sensitivity in hypertensive postmenopausal women
16. The effect of losartan on insulin resistance and beta cell function in chronic hemodialysis patients
17. New-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE)
18. Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study
19. Hypothesis: Beta-adrenergic receptor blockers and weight gain: A systematic analysis
20. Merck reports additional subgroup analyses from LIFE study with investigational use of cozaar; results suggest effect of cozaar different in black patient subpopulation in study (press release)
21. Post-stroke antihypertensive study
22. Randomized trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack
23. Losartan and uric acid
24. Prognostic significance of uric acid serum concentration in patients with acute ischemic stroke
25. Clinical pharmacology of the angiotensin-receptor antagonists
26. Dosing angiotensin II blockers-beyond blood pressure
27. Angiotensin II type 1 receptor blockers
28. The pharmacokinetics of irbesartan in renal failure and maintenance hemodialysis
29. The pharmacokinetics of losartan in renal insufficiency